Latest & greatest articles for topiramate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on topiramate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on topiramate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for topiramate

21. Qsymia (phentermine and topiramate extended-release)

Qsymia (phentermine and topiramate extended-release) Drug Approval Package: Qsymia (phentermine and topiramate extended-release) NDA #22580Orig1s000 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Qsymia (phentermine and topiramate extended-release) Capsules CIV Company: Vivus, Inc. Application No.: 22580Orig1s000 Approval Date: 07/17/2012 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634

FDA - Drug Approval Package2012

22. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. 21481449 2011 04 18 2011 04 28 2015 06 16 1474-547X 377 9774 2011 Apr 16 Lancet (London, England) Lancet Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo (...) -controlled, phase 3 trial. 1341-52 10.1016/S0140-6736(11)60205-5 Obesity is associated with a reduction in life expectancy and an increase in mortality from cardiovascular diseases, cancer, and other causes. We therefore assessed the efficacy and safety of two doses of phentermine plus topiramate controlled-release combination as an adjunct to diet and lifestyle modification for weight loss and metabolic risk reduction in individuals who were overweight and obese, with two or more risk factors

Lancet2011

23. Clinical Assessment of Topiramate Therapy in Patients With Migrainous Vertigo

Clinical Assessment of Topiramate Therapy in Patients With Migrainous Vertigo 19656221 2010 05 11 2010 08 18 2013 08 21 1526-4610 50 1 2010 Jan Headache Headache Clinical assessment of topiramate therapy in patients with migrainous vertigo. 77-84 10.1111/j.1526-4610.2009.01496.x To assess the efficacy of topiramate in reducing both the frequency and the severity of vertigo and headache attacks in patients with migrainous vertigo and to compare 50 and 100 mg/day doses of the drug. Thirty (...) patients diagnosed as definite migrainous vertigo were recruited in the study. Vertigo and headache frequency was determined as the monthly number of attacks whereas severity was determined by visual analog scales measured in millimeters from 0 to 100. Patients were randomized to either 50 or 100 mg/day topiramate for 6 months. Vertigo and headache frequency and severity were evaluated at the end of the study period. Number of mothly vertigo attacks decreased significantly in the overall group after

EvidenceUpdates2010

24. New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate

New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate Article Text

Evidence-Based Mental Health2010

25. Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom

Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom Verdian L, Yi Y Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of the addition of rufinamide compared with topiramate or lamotrigine for children with Lennox-Gastaut Syndrome that was uncontrolled by up to three traditional

NHS Economic Evaluation Database.2010

26. Ocular side effects of Topiramate: Frequently asked questions

Ocular side effects of Topiramate: Frequently asked questions The Royal College of Ophthalmologists Ocular side effects of Topiramate- Frequently asked questions 1. What is Topiramate and when is it indicated clinically? Topiramate is a sulfamate-substituted monosaccharide derived from D-fructose. Its is used mainly as an antiepileptic drug both as mono-therapy and as an adjunct in the control of partial and primary generalised epilepsy in adults and children above the age of two 1-3 (...) . Effectiveness in migraine prophylaxis, trigeminal neuralgia, bipolar disorders, depression and eating disorders has also been reported 4-8 . Recently it is been used to treat idiopathic intracranial hypertension 9, 10 . In an open label study it has been show to be as effective as acetazolamide in the treatment of intracranial hypertension 11 . 2. How does topiramate work? It, acts predominantly by inactivating the sodium and or calcium gate channels, hyperpolarising K + currents, inhibition of kainate

Royal College of Ophthalmologists2010

27. Review of the Ocular side effects of Topiramate

Review of the Ocular side effects of Topiramate RCOphth reference: 2010/PROF/122 Original document 2006 Reviewed October 2010 1 A Review of the Ocular side effects of Topiramate Author: Patrick Watts This manuscript was reviewed by Paediatric Ophthalmology Subcommittee, Royal College of Ophthalmologists Address for Correspondence: Mr Patrick Watts Department of Ophthalmology University Hospital of Wales Cardiff CF14 4XW Telephone: (+44) 2920748583 Fax: (+44) 2920748240 Keywords: Topiramate (...) , Glaucoma RCOphth reference: 2010/PROF/122 Original document 2006 Reviewed October 2010 2 Abstract Acute angle closure glaucoma and visual blurring due to induced myopia have been reported with the use of the antiepileptic drug topiramate. Various hypotheses have been put forward to explain the mechanism of the aforementioned ocular side effects. These presumed ocular side effects of topiramate have included patients treated with other drugs such as serotonin reuptake inhibitors which are also reported

Royal College of Ophthalmologists2010

28. Topiramate to Prevent Pediatric Migraine Headaches: A Systematic Review

Topiramate to Prevent Pediatric Migraine Headaches: A Systematic Review "Topiramate to Prevent Pediatric Migraine Headaches: A Systematic Revie" by Tammy L. Wilson < > > > > > Title Author Date of Award 10-2010 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Torry Cobb Rights . Abstract Objectives: Neurogenic inflammation plays a key part in the development and continuation of migraine headaches. Treatment of migraines includes acute (...) attack medications, avoidance of triggers, and preventative treatment. Currently there are no FDA approved preventative medications for treatment of pediatric migraines. Pediatric migraines have long been unrecognized and undertreated. This systematic review evaluates RCT’s that have studied prophylactic treatment of migraines with topiramate. Methods: An thorough search of PubMed, Medline, Cinhahl, and EBM Reviews of the Pacific University Library Database which compiles the Cochrane Database

Pacific University EBM Capstone Project2010

29. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age

Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age 19255022 2009 03 03 2009 03 30 2013 08 21 1098-4275 123 3 2009 Mar Pediatrics Pediatrics Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age. 924-34 10.1542/peds.2008-0642 Currently, no drugs are Food and Drug (...) Administration-approved for migraine prophylaxis in pediatric patients. The objective of this study was to evaluate the efficacy and safety of topiramate for migraine prevention in adolescents. Adolescents (12-17 years of age) with a >/=6-month history of migraine were assigned randomly to receive 16 weeks of daily treatment with topiramate (50 or 100 mg/day) or placebo. The primary efficacy measure was the percent reduction in monthly migraine attacks, with the use of the 48-hour rule, from the prospective

EvidenceUpdates2009

30. Are migraineurs at increased risk of adverse drug responses: a meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine

Are migraineurs at increased risk of adverse drug responses: a meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine Are migraineurs at increased risk of adverse drug responses: a meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine Are migraineurs at increased risk of adverse drug responses: a meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine Luykx J, Mason M, Ferrari (...) M D, Carpay J CRD summary The authors concluded that an equivalent dose of topiramate was associated with different adverse drug reactions and a higher likelihood of drug-related withdrawal from treatment in patients with migraine than in patients with epilepsy. Given the marked differences between trials and the questionable relevance of comparisons made in the review, the reliability and clinical significance of these findings is unclear. Authors' objectives To compare adverse drug reactions

DARE.2009

31. Topiramate add-on for drug-resistant partial epilepsy.

Topiramate add-on for drug-resistant partial epilepsy. BACKGROUND: The majority of people with epilepsy have a good prognosis and their seizures are controlled by a single antiepileptic drug. However, up to 20% of patients from population-based studies and up to 30% from clinical series (not population-based) develop drug-resistant epilepsy, especially those with partial onset seizures. In this review we summarize the current evidence regarding a new antiepileptic drug, topiramate, when used (...) as an add-on treatment for drug-resistant partial epilepsy. OBJECTIVES: To evaluate the efficacy and safety of topiramate when used as an add-on treatment for drug-resistant partial epilepsy. SEARCH STRATEGY: We searched the Cochrane Epilepsy Group Specialized Register (10 May 2007); the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 3, 2007). No language restrictions were imposed. We also contacted the manufacturers of topiramate and researchers in the field to see

Cochrane2008

32. Topiramate improves psychopathological symptoms and quality of life in women with borderline personality disorder

Topiramate improves psychopathological symptoms and quality of life in women with borderline personality disorder Topiramate improves psychopathological symptoms and quality of life in women with borderline personality disorder | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Topiramate improves psychopathological symptoms and quality of life in women with borderline personality disorder Article Text Therapeutics Topiramate improves psychopathological symptoms and quality of life in women with borderline personality disorder Statistics from

Evidence-Based Mental Health2007

33. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial

The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial Marson A G, Al (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The authors assessed valproate, lamotrigine and topiramate. Drug dosages and preparations were used as the clinician would use them in everyday practice. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population comprised patients with suspected epilepsy. Patients were included if they "had a history of two or more clinically definite

NHS Economic Evaluation Database.2007

34. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The authors assessed five antiepileptic drugs. These were carbamazepine, gabapentin, lamotrigine, oxcarbazepine and topiramate. The drug dosages and preparations were used as they would be by a clinician in everyday practice. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population

NHS Economic Evaluation Database.2007

35. Topiramate for treating alcohol dependence: a randomized controlled trial.

Topiramate for treating alcohol dependence: a randomized controlled trial. 17925516 2007 10 10 2007 10 17 2016 10 17 1538-3598 298 14 2007 Oct 10 JAMA JAMA Topiramate for treating alcohol dependence: a randomized controlled trial. 1641-51 Hypothetically, topiramate can improve drinking outcomes among alcohol-dependent individuals by reducing alcohol's reinforcing effects through facilitation of gamma-aminobutyric acid function and inhibition of glutaminergic pathways in the corticomesolimbic (...) system. To determine if topiramate is a safe and efficacious treatment for alcohol dependence. Double-blind, randomized, placebo-controlled, 14-week trial of 371 men and women aged 18 to 65 years diagnosed with alcohol dependence, conducted between January 27, 2004, and August 4, 2006, at 17 US sites. Up to 300 mg/d of topiramate (n = 183) or placebo (n = 188), along with a weekly compliance enhancement intervention. Primary efficacy variable was self-reported percentage of heavy drinking days

JAMA2007

36. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial.

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. 17382827 2007 03 26 2007 04 05 2017 02 19 1474-547X 369 9566 2007 Mar 24 Lancet (London, England) Lancet The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. 1000-15 Carbamazepine (...) carbamazepine was deemed to be standard treatment, and they were randomly assigned to receive carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate. Primary outcomes were time to treatment failure, and time to 12-months remission, and assessment was by both intention to treat and per protocol. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN38354748. For time to treatment failure, lamotrigine was significantly better than carbamazepine (hazard

Lancet2007 Full Text: Link to full Text with Trip Pro

37. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.

The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. 17382828 2007 03 26 2007 04 05 2016 12 28 1474-547X 369 9566 2007 Mar 24 Lancet (London, England) Lancet The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. 1016-26 Valproate is widely accepted as a drug of first choice (...) for patients with generalised onset seizures, and its broad spectrum of efficacy means it is recommended for patients with seizures that are difficult to classify. Lamotrigine and topiramate are also thought to possess broad spectrum activity. The SANAD study aimed to compare the longer-term effects of these drugs in patients with generalised onset seizures or seizures that are difficult to classify. SANAD was an unblinded randomised controlled trial in hospital-based outpatient clinics in the UK. Arm B

Lancet2007 Full Text: Link to full Text with Trip Pro

38. Cost-effectiveness of migraine prevention: the case of topiramate in the UK.

Cost-effectiveness of migraine prevention: the case of topiramate in the UK. The aim of this study was to assess the cost-effectiveness of topiramate vs. no preventive treatment in the UK. Model inputs included baseline migraine frequency, treatment discontinuation and response, preventive and acute medical cost per attack [2005 GBP ( pound)] and gain in health utility. Outcomes included monthly migraines averted, acute and preventive treatment costs and cost per quality-adjusted life year (...) (QALY). Topiramate was associated with 1.8 fewer monthly migraines and a QALY gain of 0.0384. The incremental cost of topiramate vs. no preventive treatment was about 10 UK pounds per migraine averted and 5700 UK pounds per QALY. Results are sensitive to baseline monthly migraine frequency, triptan use rate and the gain in utility. Incorporating savings from reduced work loss (about 36 UK pounds per month) suggests that topiramate would be cost saving compared with no preventive treatment

EvidenceUpdates2006

39. Topiramate for acute affective episodes in bipolar disorder.

Topiramate for acute affective episodes in bipolar disorder. BACKGROUND: Bipolar disorder is a common recurrent illness with high levels of chronicity. Treatment resistance persists despite the use of established medications, such as lithium and valproate. New medications are required for the treatment of refractory cases. Retrospective and open-label trials have suggested that the anticonvulsant topiramate may be efficacious in bipolar disorder. There is a need to clarify the evidence (...) available in the form of randomised controlled trials for its use in bipolar disorder. OBJECTIVES: To review the evidence for the efficacy and acceptability of topiramate in the treatment of acute mood episodes in bipolar disorder. SEARCH STRATEGY: The Cochrane Collaboration Depression, Anxiety and Neurosis (CCDAN) group search strategy was used. The following databases were searched:The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register (CCDANCTR), September 2003

Cochrane2006

40. Cost effectiveness of topiramate in the prevention of migraines in the United States: an update

Cost effectiveness of topiramate in the prevention of migraines in the United States: an update Cost effectiveness of topiramate in the prevention of migraines in the United States: an update Cost effectiveness of topiramate in the prevention of migraines in the United States: an update Brown J S, Rupnow M F, Neumann P, Friedman M, Menzin J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study investigated the use of topiramate (100 mg/day) in the prevention of migraine. This intervention was compared with no preventive treatment. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised working adults who were appropriate candidates for migraine

NHS Economic Evaluation Database.2006